Designing Antibiotics with Inherent Efflux Resistance: ERB-Modified Fluoroquinolones

Mark Laws reports a dataset on novel Efflux Resistance Breaker (ERB)-modified fluoroquinolone antibiotics. The data includes MIC values, gyrase inhibition IC50, and in vivo efficacy from a murine thigh infection model, published on figshare in May 2026. The compounds KSN-L22 and BL-7 showed activity against multidrug-resistant strains including MRSA, VRE, and Acinetobacter baumannii.

Use Cases

• Training predictive models for antibiotic activity based on MIC reduction data mentioned in the description
• Analyzing structure-activity relationships for efflux-resistant compounds based on the reported lead compounds KSN-L22 and BL-7
• Benchmarking pharmacokinetic profiles for oral antibiotics based on the reported PK/PD and toxicity data

Strengths

• Includes specific quantitative results such as a 512-fold reduction in MIC and IC50 values of ~3.8 μg/mL for DNA gyrase inhibition
• Reports in vivo efficacy data showing a >4-log bacterial load reduction in a murine model at a 50 mg/kg oral dose
• Describes a focused chemical strategy (ERB technology) with tested lead compounds against a defined panel of multidrug-resistant pathogens

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is small at 463.4 KB, indicating limited scope

Provenance

Source

Mark Laws via figshare

Collection Method

Likely contains experimental results from chemical synthesis, microbiological assays, and animal studies.

Freshness

Last updated 2026-05-29 04:48:36; freshness should be verified